Investment Rating - The report maintains an "Accumulate" rating for the company [2][7] Core Views - The company is accelerating the application of AI and quantum technology in high-end research and manufacturing, while steadily expanding its overseas operations to enhance performance [6] - The company forecasts a revenue of 2.48 to 2.6 billion yuan for 2024, representing a year-on-year growth of 10.81% to 16.17%, and a net profit attributable to shareholders of 65 to 95 million yuan, marking a significant turnaround from losses [6] - The company has established strategic partnerships to develop a new materials research and manufacturing system supported by quantum technology and AI, aiming to promote the commercialization of quantum technology [6] Summary by Sections Financial Data - Total market capitalization is 4.305 billion yuan, with a circulating market value of 4.300 billion yuan [5] - The stock has a 52-week high of 17.99 yuan and a low of 6.36 yuan, with a 52-week increase of 113.40% [5] - The company expects to achieve a net profit of 0.93, 2.02, and 3.08 billion yuan for the years 2024 to 2026, with corresponding P/E ratios of 46.46, 21.35, and 14.00 [7][9] Business Development - The company is set to accelerate its overseas business starting in the second half of 2024, which is expected to significantly improve its performance due to higher profit margins in international markets [6] - The company has announced collaborations with notable partners, including a 2 billion yuan fund for digital economy investments and strategic agreements with quantum technology centers [6] Investment Outlook - The report highlights the strong background of the company's investment partners, which is expected to enhance the company's valuation and profitability [6] - The integration of AI with the company's core business is anticipated to optimize costs and improve profitability, thereby expanding growth potential [6]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [4]. Core Views - The government has increased support for innovative drugs, which is expected to promote healthy development across various segments of the pharmaceutical industry [6][32]. - The report emphasizes a positive outlook for the pharmaceutical sector, particularly in the context of recent government policies aimed at enhancing healthcare services and drug innovation [27][32]. Summary by Sections Weekly Market Review - The pharmaceutical and biotechnology index rose by 2.02%, outperforming the CSI 300 index by 0.64 percentage points, ranking 18th in industry performance [9]. - Year-to-date, the index has increased by 6.53%, again surpassing the CSI 300 by 6.3 percentage points, ranking 14th [9]. - Sub-sectors such as medical services and medical devices showed significant gains, with medical services up 3.7% and medical devices up 3.29% for the week [13]. Individual Stock Performance - In the A-share market, 321 out of 477 pharmaceutical stocks rose, with notable gainers including Hotgen Biotech (+38.63%) and Berry Genomics (+34.39%) [18]. - In the Hong Kong market, 78 out of 106 pharmaceutical stocks increased, with top performers being HeartFlow Medical-B (+31.87%) and Hengrui Medicine-B (+30.19%) [22]. Industry News and Policies - The government work report highlighted the need for a collaborative approach to healthcare, emphasizing the integration of medical services, insurance, and pharmaceuticals [27]. - Key policies include optimizing drug procurement, enhancing quality assessments, and increasing financial support for basic medical insurance [33]. Weekly Insights - The report reiterates a bullish stance on the pharmaceutical sector, particularly in light of government initiatives to support innovative drug development and improve healthcare financing [32][34]. - Specific recommendations include focusing on companies in various segments such as raw materials, chemical preparations, and medical services, with suggested stocks like Hengrui Medicine and WuXi AppTec [34].

[Table_Title] 通信行业周报 AI应用再提速，寻找端侧硬件机会 2025 年 03 月 10 日 [Table_Summary] 【投资要点】 【市场回顾】 1）通信行业整体上涨：通信行业跑赢大盘，申万通信指数周内上涨 2.8%；2）板块估值处于历史较高水平：通信板块当前整体动态市盈 率约为 22 倍 PE，高于过去两年中枢；3）细分领域普遍上涨：工业互 联网、电力通信、5G 周内涨幅分别为 16.1%、11.7%、8.0%；4）个股 表现：113 家上涨，18 家下跌，其中亿通科技、利尔达、东软载波、 云里物里、*ST 信通过去一周涨幅分别为 42.3%、33.7%、29.9%、29.9%、 27.6%。 【配置建议】 政府工作报告明确 2025 年 5G、AI、数据与算力、低空经济为重点发 展领域，AI 技术突破持续加速商业化应用落地，建议关注应用侧硬件 机会，包括端侧 AI 芯片（瑞芯微、乐鑫科技等）、通信模组（移远通 信、广和通等）、机器人方向（拓邦股份、和而泰等）、智驾方向（珠 城科技等）。 【风险提示】 证券分析师：马成龙 《DeepSeek 加速算力基建革命，看好 AI 应用》 20 ...

行 业 研 究 / 建 筑 装 饰 / 证 券 研 究 报 告 [Table_Title] 建筑装饰行业周报 政策稳中求进，关注低位央企和转型AI 算力等业务企业机会 1）主线一：推荐建筑央企。推荐【中国铁建】、【中国中铁】、【中国 交建】、【中国建筑】、【中国能建】、【中国电建】、【中国中冶】，关注 【中国化学】、【中材国际】、【中钢国际】、【中工国际】、【北方国际】。 2）主线二：推荐高景气赛道产业链重点企业。隧道掘进设备行业： 推荐【铁建重工】、【中铁工业】，关注【五新隧装】；民爆行业：推荐 【易普力】，【高争民爆】，关注【雅化集团】、【保利联合】等；岩土 工程行业：推荐【中岩大地】。 3）主线三：关注顺周期及布局转型 AI/机器人等新质生产力方向的优 质标的机会。推荐【罗曼股份】，关注【海南华铁】、【宁波建工】、【深 城交】、【鸿路钢构】、【深圳瑞捷】、【金诚信】。 【风险提示】 2025 年 03 月 09 日 [Table_Summary] 【投资要点】 2）3 月进入业绩披露期，关注业务布局高景气赛道、业绩表现较优的 建筑企业。本周浦东建设、安徽建工等景气区域地方国企公告经营情 况。浦东建设 2 ...

[Table_Title] 建材行业周报 政策稳中求进、水泥持续复价，继续关 注建材春季躁动及数字化转型机会 2025 年 03 月 09 日 [Table_Author] 东方财富证券研究所 证券分析师：王翩翩 证书编号：S1160524060001 证券分析师：郁晾 证书编号：S1160524100004 证券分析师：姚旭东 证书编号：S1160525010001 [Table_PicQuote] 相对指数表现 -21.64% -13.20% -4.75% 3.69% 12.13% 20.58% 3/7 5/7 7/7 9/7 11/7 1/7 3/7 建筑材料 沪深300 [Table_Summary] 【投资要点】 【配置建议】 【风险提示】 需求不及预期，毛利率不及预期，回款不及预期。 挖掘价值 投资成长 强于大市（维持） [Table_Report] 相关研究 《立邦 2024 年 TUC 业务逆势增长， 指引乐观，2025 行业或迎向上拐点》 2025.03.03 《实物量和二手销售景气修复，水泥 玻纤龙头竞合策略改善，重视建材春 季躁动》 2025.03.02 《复工实物量温和回升、华东水泥开 ...

Group 1 - The report highlights a positive change in liquidity, continuing to recommend trading opportunities in long-term bonds, specifically 10Y and 30Y government bonds, based on expectations from the upcoming Two Sessions policy [1][9][4] - Since the beginning of 2025, interbank liquidity has been tightening, primarily due to a continuous reduction in net funding from major banks and increased net payments of government bonds, leading to a migration of funds towards the fiscal system [4][7][8] - The interbank repo market has experienced a "volume reduction and price increase" trend, with the DR001 rate rising from 1.55% on January 2 to 1.86% by February 28, while the transaction volume in the repo market decreased from 6.6 trillion to 4.2 trillion [4][7][8] Group 2 - In the last week of February 2025, there was a positive change in supply and demand in the interbank repo market, with the total market balance of pledged repo bonds increasing from 9.2 trillion to 9.5 trillion, indicating some funds are optimistic about future market conditions [8][16] - The net funding from major banks rose to approximately 1.5 trillion, marking a new high for February, while the Shibor 3M rate reached 1.92%, indicating ongoing pressure on the banking system's liabilities [8][16][18] - The report notes that the leverage ratio in the market increased to 106.4%, with non-legal person products reaching 112.4%, suggesting a higher risk appetite among market participants [18][20] Group 3 - The report provides a review of the interbank liquidity supply and demand, indicating that net funding from major banks increased by 1,857 billion, while the total market balance of pledged repo bonds rose by 3,274 billion [16][17] - The interbank certificate of deposit market showed mixed results, with the issuance volume for the week totaling 720.7 billion, reflecting a slight increase from the previous week [21][23] - The report also highlights the yield spreads between various financial instruments, noting that the yield on 1-year AAA-rated interbank certificates of deposit was -15 basis points compared to the R007 rate, indicating a tightening spread [28][30]

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [5] Core Viewpoints - The AI concept has experienced a pullback, but the upward momentum for innovative drugs is expected to continue [1][2] - The pharmaceutical index fell by 2.15% last week, outperforming the CSI 300 index by 0.07 percentage points, ranking 25th in industry performance [10] - The healthcare services sub-sector has shown the highest growth since the beginning of 2025, with a rise of 12.31% [16] - The report highlights the strong performance of innovative drugs and companies with positive earnings forecasts, such as Nocera Health and Newnovel [19][31] Market Performance Summary - The pharmaceutical index has increased by 4.17% year-to-date, outperforming the CSI 300 index by 5.31 percentage points, ranking 12th in industry performance [10] - The best-performing stocks in the A-share market last week included Nocera Health (+20.98%), Changyao Holdings (+20.96%), and Shanghai Yizhong (+18.78%) [19] - In the Hong Kong stock market, 30 out of 106 pharmaceutical stocks rose, accounting for 28.3% [23] Sub-industry Performance - The sub-industry with the smallest decline last week was Traditional Chinese Medicine, down 0.35%, while the largest decline was in pharmaceutical commerce, down 3.44% [14] - Year-to-date, the Traditional Chinese Medicine sub-sector has decreased by 5.29%, while healthcare services have increased by 12.31% [16] Industry News and Policies - Starting March 1, Guangxi will implement centralized procurement for large medical equipment, aiming to reduce costs through bulk purchasing [27][28] - Huadong Medicine's ADC innovative drug has received orphan drug designation from the FDA, which provides various incentives for the company [29] Company Announcements - Notable company announcements include Nocera Health's significant R&D progress and Newnovel's exclusive cooperation agreement with RadianceBiopharma, potentially worth $1.23 billion [19][31]

Investment Rating - The report maintains an "Outperform" rating for the industry [5] Core Insights - The importance of the domestic AI supply chain has increased following OpenAI's announcement to terminate API services to China, prompting several domestic large model vendors to offer migration services [3] - Companies like Zhipu AI and Baidu Smart Cloud are providing extensive support and free tokens to facilitate the transition for users migrating from OpenAI to domestic models [3] - This shift is expected to enhance the technical capabilities and product performance of domestic large models, thereby improving China's AI autonomy and security [3] Summary by Sections Industry Dynamics - Multiple domestic large model vendors are now offering migration services in response to OpenAI's API service termination for China [3] - Zhipu AI is providing a comprehensive migration plan, including 150 million tokens and training for developers transitioning from OpenAI [3] - Baidu Smart Cloud has launched a zero-cost plan for new enterprise users, offering free access to its flagship models and additional tokens for OpenAI users [3] - Alibaba Cloud is also stepping in with competitive alternatives and migration support for OpenAI API users [3] Recommendations - The report suggests monitoring large model vendors such as iFlytek, Kunlun Wanwei, and 360, as well as domestic computing and server manufacturers like Jingjiawei, Cambrian, and Shenzhou Digital [3]

Investment Rating - The report maintains an "Outperform" rating for the industry [4] Core Insights - A new round of fiscal and tax system reform is expected to drive the construction of fiscal and tax information systems, as highlighted in the State Council's audit report [3] - The report emphasizes the need for enhanced tax collection management and improved data sharing among departments, addressing issues such as inaccurate accounting information in state-owned enterprises and irregularities in credit allocation [3] - The modernization of the fiscal and tax system will leverage information systems to support a comprehensive monitoring mechanism for transfer payment funds, enhancing budget management at the provincial level [3] - The transition towards a digital tax collection system aims to shift taxpayers from "passive compliance" to "active compliance" and ultimately to "automatic compliance," utilizing technology as a foundation for tax compliance [3] - Companies to watch include Tax Friend Co., Ltd., Jincai Hulin, China Software, and Boshi Software [3] Summary by Sections Fiscal and Tax System Reform - The report discusses the State Council's audit report which suggests optimizing the fiscal system through a new round of reforms, focusing on the division of fiscal responsibilities and enhancing transfer payments [2][3] Information System Development - The report outlines the role of information systems in modernizing the fiscal and tax framework, including the establishment of personal income and asset information systems and integrated budget management systems [3] Digital Transformation in Taxation - The report highlights the digital transformation in tax collection, aiming to create a smart tax system that integrates taxpayer, tax authority, and decision-maker platforms [3]

Investment Rating - The report assigns an "Accumulate" rating for the company, marking the first coverage of the stock [1]. Core Views - The acquisition of Xinlian Yuezhou aims to expand silicon-based capacity and strengthen SiC competitiveness, enhancing the company's growth potential [1][4]. - The transaction is expected to improve the company's control over Xinlian Yuezhou, promoting the development of SiC and high-voltage analog IC businesses, while integrating production capacity for better profitability and market competitiveness [5][6]. Summary by Sections Acquisition Details - On June 22, 2024, the company announced plans to acquire the remaining 72.33% stake in its subsidiary Xinlian Yuezhou through a combination of share issuance and cash payment. The share issuance price is set at 4.04 CNY per share, with a lock-up period of 12 months [4]. - Xinlian Yuezhou has rapidly developed its business in silicon carbide (SiC), with a production capacity of approximately 70,000 pieces per month. The company has achieved significant breakthroughs in SiC MOSFETs, leading the domestic market in shipment volume in 2023 [4]. Financial Projections - Revenue projections for 2024, 2025, and 2026 are estimated at 67.67 billion CNY, 82.17 billion CNY, and 99.60 billion CNY, respectively. The net profit attributable to the parent company is projected to be -1.26 billion CNY in 2024, -738.86 million CNY in 2025, and a positive 102.80 million CNY in 2026 [6][7]. - The report anticipates a revenue growth rate of 27.08% in 2024, followed by 21.44% in 2025 and 21.21% in 2026 [7]. Market Context - The acquisition aligns with the recent regulatory support from the China Securities Regulatory Commission for mergers and acquisitions in the hard technology sector, indicating a favorable environment for the company's strategic moves [5][6].